Galapagos licenses Organoid Technology from the HUB foundation for use in cystic fibrosis and IBD research

August 6, 2015

Hubrecht Organoid Technology

Galapagos NV (Euronext & NASDAQ: GLPG) announced on July 14th 2015 that it has entered into a licensing agreement with the HUB foundation for use of Organoid Technology for pre-clinical research in cystic fibrosis (CF) and inflammatory bowel disease (IBD).
Read more

copyrights 2014 Hubrecht Organoid Technology